CT引导下经皮穿刺微波消融治疗肺癌的临床应用

摘要

目的 探讨CT引导下对肺癌患者行微波消融治疗的临床效果.方法 对2013年3月～2016年3月在CT引导下经皮穿刺微波消融(PMAT)治疗的38例肺癌患者,共45个消融病灶的临床资料,根据改良的实体瘤疗效评价标准评价疗效,根据肿瘤消融国际工作组制定的标准对并发症进行评估.结果 治疗后6个月所有病灶达到CR(26/45,占57.8％),达到PR(9/45,占20.0％);总体有效率(CR+PR)为77.8％;1、2、3年生存率分别为89.5％(34/38)、73.7％(28/38)、63.2％(24/38).38例患者中,出现气胸8例,发热13例,咯血5例,心房纤颤1例.结论 CT引导经皮穿刺微波消融治疗对不愿或不能进行手术治疗的肺癌患者有较确切的临床疗效,且安全可靠.%Objective To explore the clinical effect of CT-guided percutaneous microwave ablation therapy (PMAT) for patients with lung cancer.Methods We analyzed the CT-guided PMAT effects for 38 patients with 45 lesions from March 2013 to March 2016 in our hospital.Modified response evaluation criteria in solid tumors (RECIST) was evaluated treatment effects and the common terminology criteria for adverse events version 4.0 (CTCAE) was assessed to complications.Results After 6 months of treatment,26 cases experienced complete response (CR) (26/45,57.8％),and 9 cases experienced partial response (PR) (9/45,20.0％) in all patients.The overall response rate was 77.8％ (CR+PR),and the 1-,2-,and 3-survival rates after PMAT were 89.5％ (34/38),73.7％ (28/38),63.2％ (24/38),respectively.Among all cases,8 cases presented with symptoms of pneumothorax.There were 13 with fever,5 with hemoptysis and 1 with auricular fibrillation.Conclusion CT-guided PMAT is a well-tolerated,safe and effective method for patients with lung cancer who they are inoperable or unwilling to accept surgical treatment.